MECKI-Amyloidosis: Assessment of the Exercise Capacity and Prognosis of Patients with Cardiac Amyloidosis

Launched by CENTRO CARDIOLOGICO MONZINO · Jan 23, 2025

Keywords

ClinConnect Summary

The MECKI-Amyloidosis clinical trial is studying how cardiac amyloidosis affects patients' ability to exercise and their long-term health outlook. Cardiac amyloidosis is a condition where abnormal proteins build up in the heart, making it harder for the heart to work properly. Over two years, the researchers will follow patients by checking their exercise capacity and other health factors every six months. They hope to develop a tool to predict the risk of serious health issues based on how well patients can exercise. This study also aims to understand how cardiac amyloidosis differs from general heart failure, which can help doctors provide better care for these patients.

To be eligible for the trial, participants must be over 18 years old and have a confirmed diagnosis of cardiac amyloidosis through specific imaging tests. They should also be able to complete a cardiopulmonary exercise test, which measures how well the heart and lungs work during physical activity. However, individuals with severe lung diseases, certain heart conditions, or other health issues that might affect exercise performance will not be included. Participants can expect regular evaluations and to contribute valuable information that may enhance treatment options for future patients with cardiac amyloidosis.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Age \> 18 years
• • Diagnosis of cardiac amyloidosis obtained by MRI or scintigraphy
• • Ability to perform a cardiopulmonary exercise test
• • Exclusion criteria
• • severe obstructive pulmonary disease
• • exercise-induced angina
• • significant ECG changes
• • presence of clinical comorbidities that interfere with exercise performance